ReviewJournal of clinical and experimental hepatology2013
Current status of immunosuppression in liver transplantation.
Review in Journal of clinical and experimental hepatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Acute and Chronic Rejection After Liver Transplantation: What A Clinician Needs to Know.Journal of clinical and experimental hepatology · 2017Review
- Individualized Immunosuppressive Protocol of Liver Transplant Recipient Should be Made Based on Splenic Function Status.Chinese medical journal · 2016Article
- Article
- Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients.British journal of clinical pharmacology · 2015Article
- Hepatobiliary quiz-8 (2013).Journal of clinical and experimental hepatology · 2013Article
- Hepatobiliary quiz-7 (2013).Journal of clinical and experimental hepatology · 2013Article
- Practice of Immunosuppression in Liver Transplant Programs in India: Results of a Survey.Journal of clinical and experimental hepatologyArticle
- The Renal Histological Correlates of Refractory Renal Dysfunction After Liver Transplantation.Journal of clinical and experimental hepatologyArticle
- Post-transplant Non-alcoholic Fatty Liver Disease and Metabolic Syndrome After Living Donor Liver Transplantation in Indians.Journal of clinical and experimental hepatologyArticle
- Algorithmic Approach to Deranged Liver Functions After Transplantation.Journal of clinical and experimental hepatologyReview
- Post Liver Transplant Renal Dysfunction-Evaluation, Management and Immunosuppressive Practice.Journal of clinical and experimental hepatologyReview
- Basics and Art of Immunosuppression in Liver Transplantation.Journal of clinical and experimental hepatologyReview
- A Case of Sirolimus-Induced Interstitial Lung Disease After Liver Transplantation.Journal of clinical and experimental hepatologyArticle
- Preventive Strategies for Nonalcoholic Fatty Liver Disease After Liver Transplantation.Journal of clinical and experimental hepatologyReview
- Long-term Management of the Adult Liver Transplantation Recipients.Journal of clinical and experimental hepatologyReview
- Nonalcoholic Fatty Liver Disease in Living Donor Liver Transplant Recipients: A Histology-Based Study.Journal of clinical and experimental hepatologyArticle
- Immunosuppressive Drugs in Liver Transplant: An Insight.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With advancements in immunosuppressive strategies and availability of better immunosuppressive agents, survival rate following liver transplantation has improved significantly in the recent times. Besides improvements in surgical techniques, the most important factor that has contributed to this better outcome is the progress made in the field of immunosuppression. Over the last several years, the trend has changed to tailored immunosuppression with the aim of achieving optimal graft function while avoiding its undesirable side effects. Induction agents are no longer used routinely and the aim is to provide minimal immunosuppression in the maintenance phase. The present review discusses the various types of immunosuppressive agents, their mechanism of action, clinical utility, advantages and disadvantages, and their side effects in short and long-term. It also discusses about tailoring immunosuppression in presence of various situations such as renal dysfunction, metabolic syndrome, hepatitis C recurrence, cytomegalovirus infections and so on. The issue of chronic kidney disease and the available renal sparing immunosuppressive strategies has been particularly stressed upon. Finally, it discusses about the practical aspects of various immunosuppression regimens including drug monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.